{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:30:34Z","timestamp":1789731034599,"version":"4.0.1"},"reference-count":168,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2 infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of candidates was evaluated, with mRNA-based vaccines emerging as leaders due to how quickly they were available for emergency use while providing a high level of efficacy. As a modular technology, the mRNA-based vaccines benefitted from decades of advancements in both mRNA and delivery technology prior to the current global pandemic. The fundamental lessons of the utility of mRNA as a therapeutic were pioneered by Dr. Katalin Kariko and her colleagues, perhaps most notably in collaboration with Drew Weissman at University of Pennsylvania, and this foundational work paved the way for the development of the first ever mRNA-based therapeutic authorized for human use, COMIRNATY\u00ae. In this Special Issue of Pharmaceutics, we will be honoring Dr. Kariko for her great contributions to the mRNA technology to treat diseases with unmet needs. In this review article, we will focus on the delivery platform, the lipid nanoparticle (LNP) carrier, which allowed the potential of mRNA therapeutics to be realized. Similar to the mRNA technology, the development of LNP systems has been ongoing for decades before culminating in the success of the first clinically approved siRNA-LNP product, ONPATTRO\u00ae, a treatment for an otherwise fatal genetic disease called transthyretin amyloidosis. Lessons learned from the siRNA-LNP experience enabled the translation into the mRNA platform with the eventual authorization and approval of the mRNA-LNP vaccines against COVID-19. This marks the beginning of mRNA-LNP as a pharmaceutical option to treat genetic diseases.<\/jats:p>","DOI":"10.3390\/pharmaceutics14020398","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T03:46:00Z","timestamp":1644810360000},"page":"398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics"],"prefix":"10.3390","volume":"14","author":[{"given":"Sean C.","family":"Semple","sequence":"first","affiliation":[{"name":"Acuitas Therapeutics, 6190 Agronomy Road, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Leone","sequence":"additional","affiliation":[{"name":"Acuitas Therapeutics, 6190 Agronomy Road, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Barbosa","sequence":"additional","affiliation":[{"name":"Acuitas Therapeutics, 6190 Agronomy Road, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying K.","family":"Tam","sequence":"additional","affiliation":[{"name":"Acuitas Therapeutics, 6190 Agronomy Road, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo J. C.","family":"Lin","sequence":"additional","affiliation":[{"name":"Acuitas Therapeutics, 6190 Agronomy Road, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Htun, Y.M., Thiha, K., Aung, A., Aung, N.M., Oo, T.W., Win, P.S., Sint, N.H., Naing, K.M., Min, A.K., and Tun, K.M. (2021). Assessment of depressive symptoms in patients with COVID-19 during the second wave of epidemic in Myanmar: A cross-sectional single-center study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252189"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/jpepsy\/jsab046","article-title":"Be My Safe Haven: Parent\u2013Child Relationships and Emotional Health During COVID","volume":"46","author":"Bate","year":"2021","journal-title":"J. Pediatr. Psychol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-021-03693-y","article-title":"BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants","volume":"596","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMc2106083","article-title":"BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants","volume":"385","author":"Liu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Liu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, K., Werner, A.P., Moliva, J.I., Koch, M., Choi, A., Stewart-Jones, G.B.E., Bennett, H., Boyoglu-Barnum, S., Shi, W., and Graham, B.S. (2021). mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv.","DOI":"10.1101\/2021.01.25.427948"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"R526","DOI":"10.1016\/j.cub.2015.05.032","article-title":"Who discovered messenger RNA?","volume":"25","author":"Cobb","year":"2015","journal-title":"Curr. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.165.8.4710","article-title":"HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response","volume":"165","author":"Weissman","year":"2000","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.4049\/jimmunol.169.9.5196","article-title":"Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference","volume":"169","author":"Capodici","year":"2002","journal-title":"J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000079987","article-title":"Exogenous siRNA Mediates Sequence-Independent Gene Suppression by Signaling through Toll-Like Receptor","volume":"177","author":"Bhuyan","year":"2004","journal-title":"Cells Tissues Organs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.172.11.6545","article-title":"Small Interfering RNAs Mediate Sequence-Independent Gene Suppression and Induce Immune Activation by Signaling through Toll-Like Receptor","volume":"172","author":"Bhuyan","year":"2004","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA Is an Endogenous Ligand for Toll-like Receptor","volume":"279","author":"Ni","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1097\/01.WCB.0000145666.68576.71","article-title":"Inhibition of Toll-like Receptor and Cytokine Signaling\u2014A Unifying Theme in Ischemic Tolerance","volume":"24","author":"Weissman","year":"2004","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immun."},{"key":"ref_18","first-page":"523","article-title":"Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development","volume":"10","author":"Weissman","year":"2007","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of Pseudouridine into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability","volume":"16","author":"Muramatsu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Karik\u00f3, K., Muramatsu, H., Ludwig, J., and Weissman, D. (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res., 39.","DOI":"10.1093\/nar\/gkr695"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/mt.2012.7","article-title":"Increased Erythropoiesis in Mice Injected with Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin","volume":"20","author":"Muramatsu","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_23","first-page":"29","article-title":"In Vitro Transcription of Long RNA Containing Modified Nucleosides","volume":"969","author":"Pardi","year":"2012","journal-title":"Vaccine Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","article-title":"HPLC Purification of In Vitro Transcribed Long RNA","volume":"969","author":"Weissman","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0076-6879(07)31011-2","article-title":"Synthesis of Anti-Reverse Cap Analogs (ARCAs) and their Applications in mRNA Translation and Stability","volume":"431","author":"Stepinski","year":"2007","journal-title":"Methods Enzymol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1081\/NCN-120022611","article-title":"Synthesis of Novel mRNA 5\u2032 Cap-Analogues: Dinucleoside P1, P3-Tri-, P1, P4-Tetra-, and P1, P5-Pentaphosphates","volume":"22","author":"Jemielity","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_27","first-page":"1486","article-title":"Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(3\u2019-O-methyl)GpppG and 7-methyl (3\u2019-deoxy)GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice","volume":"53","author":"Laczko","year":"2020","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","article-title":"Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques","volume":"15","author":"Pardi","year":"2019","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pardi, N., Secreto, A.J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B.L., and Tam, Y.K. (2017). Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun., 8.","DOI":"10.1038\/ncomms14630"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2012.12.029","article-title":"Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format","volume":"166","author":"Phua","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1073\/pnas.84.21.7413","article-title":"Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure","volume":"84","author":"Felgner","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.gt.3300821","article-title":"Stabilized plasmid-lipid particles: Construction and characterization","volume":"6","author":"Wheeler","year":"1999","journal-title":"Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/10611860009102217","article-title":"Encapsulation of Plasmid DNA in Stabilized Plasmid\u2013Lipid Particles Composed of Different Cationic Lipid Concentration for Optimal Transfection Activity","volume":"7","author":"Saravolac","year":"2000","journal-title":"J. Drug Target."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0005-2736(99)00059-0","article-title":"Stabilized plasmid-lipid particles: Factors influencing plasmid entrapment and transfection properties","volume":"1419","author":"Mok","year":"1999","journal-title":"Biochim. et Biophys. Acta (BBA)-Biomembr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/sj.gt.3300965","article-title":"Stabilized plasmid-lipid particles for regional gene therapy: Formulation and transfection properties","volume":"6","author":"Zhang","year":"1999","journal-title":"Gene Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","article-title":"Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: Formation of novel small multilamellar vesicle structures","volume":"1510","author":"Semple","year":"2001","journal-title":"Biochim. et Biophys. Acta (BBA)-Biomembr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0076-6879(00)13020-4","article-title":"Lipid-based formulations of antisense oligonucleotides for systemic delivery applications","volume":"313","author":"Semple","year":"2000","journal-title":"Methods Enzymol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0006-3495(01)76202-9","article-title":"Spontaneous Entrapment of Polynucleotides upon Electrostatic Interaction with Ethanol-Destabilized Cationic Liposomes","volume":"80","author":"Maurer","year":"2001","journal-title":"Biophys. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.gt.3300707","article-title":"Stable and monodisperse lipoplex formulations for gene delivery","volume":"5","author":"Zelphati","year":"1998","journal-title":"Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1021\/ja0318030","article-title":"Controlled Vesicle Self-Assembly in Microfluidic Channels with Hydrodynamic Focusing","volume":"126","author":"Jahn","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0006-3495(03)74558-5","article-title":"The Shape Parameter of Liposomes and DNA-Lipid Complexes Determined by Viscometry Utilizing Small Sample Volumes","volume":"85","author":"Sun","year":"2003","journal-title":"Biophys. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11095-004-1873-z","article-title":"A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA","volume":"22","author":"Jeffs","year":"2005","journal-title":"Pharm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Belliveau, N., Huft, J., Lin, P.J., Chen, S., Leung, A.K., Leaver, T.J., Wild, A.W., Lee, J.B., Taylor, R.J., and Tam, Y.K. (2012). Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol. Ther.-Nucleic Acids, 1.","DOI":"10.1038\/mtna.2012.28"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.cgt.7700326","article-title":"Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line","volume":"8","author":"Leonetti","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"ref_50","first-page":"1185","article-title":"Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles","volume":"298","author":"Mui","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12881","DOI":"10.1073\/pnas.1306529110","article-title":"Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery","volume":"110","author":"Alabi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nano.2012.05.019","article-title":"Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA","volume":"9","author":"Lin","year":"2013","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00103-X","article-title":"Roles of lipid polymorphism in intracellular delivery","volume":"47","author":"Hafez","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","article-title":"On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids","volume":"8","author":"Hafez","year":"2001","journal-title":"Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-4615-5833-0_10","article-title":"Acidification of Lysosomes and Endosomes","volume":"27","year":"1996","journal-title":"Subcell. Biochem."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Mui, B.L., Tam, Y.K., Jayaraman, M., Ansell, S.M., Du, X., Tam, Y.Y.C., Lin, P.J., Chen, S., Narayanannair, J.K., and Rajeev, K.G. (2013). Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol. Ther.-Nucleic Acids, 2.","DOI":"10.1038\/mtna.2013.66"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics with Endogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kumar, V., Qin, J., Jiang, Y., Duncan, R.G., Brigham, B., Fishman, S., Nair, J.K., Akinc, A., Barros, S.A., and Kasperkovitz, P.V. (2014). Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy. Mol. Ther.-Nucleic Acids, 3.","DOI":"10.1038\/mtna.2014.61"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","article-title":"Lipid-like materials for low-dose, in vivo gene silencing","volume":"107","author":"Love","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-800148-6.00003-1","article-title":"Nanotechnology for In vivo Targeted siRNA Delivery","volume":"88","author":"Dahlman","year":"2014","journal-title":"Adv. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2015.01.007","article-title":"Preclinical and clinical development of siRNA-based therapeutics","volume":"87","author":"Ozcan","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid"},{"key":"ref_74","first-page":"703","article-title":"Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"267","author":"Berk","year":"2019","journal-title":"J. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","article-title":"Non-viral Delivery of Zinc Finger Nuclease mRNA Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets","volume":"27","author":"Conway","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chom.2020.11.012","article-title":"D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization","volume":"29","author":"Weissman","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"McKay, P.F., Hu, K., Blakney, A.K., Samnuan, K., Brown, J.C., Penn, R., Zhou, J., Bouton, C.R., Rogers, P., and Polra, K. (2020). Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun., 11.","DOI":"10.1038\/s41467-020-17409-9"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41551-020-00671-z","article-title":"In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA","volume":"5","author":"Villiger","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Saunders, K.O., Pardi, N., Parks, R., Santra, S., Mu, Z., Sutherland, L., Scearce, R., Barr, M., Eaton, A., and Hernandez, G. (2021). Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. NPJ Vaccines, 6.","DOI":"10.1038\/s41541-021-00307-6"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/acs.nanolett.5b02428","article-title":"Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo","volume":"16","author":"Dong","year":"2016","journal-title":"Nano Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/adma.201505822","article-title":"Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery","volume":"28","author":"Fenton","year":"2016","journal-title":"Adv. Mater."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","article-title":"Systemic delivery of factor IX messenger RNA for protein replacement therapy","volume":"114","author":"Ramaswamy","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2017.12.024","article-title":"Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency","volume":"26","author":"Prieve","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jhep.2020.12.010","article-title":"Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB\/c.Abcb4 (-\/-) mouse model of PFIC3","volume":"74","author":"Wei","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ymthe.2019.04.017","article-title":"mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency","volume":"27","author":"Cao","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","article-title":"Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles","volume":"20","author":"Chen","year":"2020","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_101","first-page":"3168","article-title":"Disease pharmacokinetic\u2013pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA -based therapies","volume":"177","author":"Fontanellas","year":"2020","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymthe.2019.09.018","article-title":"Novel mRNA-Based Therapy Reduces Toxic Galactose Metabolites and Overcomes Galactose Sensitivity in a Mouse Model of Classic Galactosemia","volume":"28","author":"Balakrishnan","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Karadagi, A., Cavedon, A.G., Zemack, H., Nowak, G., Eybye, M.E., Zhu, X., Guadagnin, E., White, R.A., Rice, L.M., and Frassetto, A.L. (2020). Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-64017-0"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kose, N., Fox, J.M., Sapparapu, G., Bombardi, R., Tennekoon, R.N., de Silva, A.D., Elbashir, S.M., Theisen, M.A., Humphris-Narayanan, E., and Ciaramella, G. (2019). A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol., 4.","DOI":"10.1126\/sciimmunol.aaw6647"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ymthe.2019.05.012","article-title":"mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo","volume":"27","author":"Rybakova","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Richner, J., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J., Julander, J.G., Tang, W., Shresta, S., and Pierson, T.C. (2017). Modified mRNA Vaccines Protect against Zika Virus Infection. Cell, 169.","DOI":"10.1016\/j.cell.2017.03.016"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Wollner, C.J., Richner, M., Hassert, M.A., Pinto, A.K., Brien, J.D., and Richner, J.M. (2021). A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses. J. Virol., 95.","DOI":"10.1128\/JVI.02482-20"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Nelson, C.S., Jenks, J.A., Pardi, N., Goodwin, M., Roark, H., Edwards, W., McLellan, J.S., Pollara, J., Weissman, D., and Permar, S.R. (2020). Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. J. Virol., 94.","DOI":"10.1128\/JVI.00186-20"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.celrep.2018.11.082","article-title":"An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections","volume":"25","author":"VanBlargan","year":"2018","journal-title":"Cell Rep."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Nguyen, Q.-T., and Choi, Y.-K. (2021). Targeting Antigens for Universal Influenza Vaccine Development. Viruses, 13.","DOI":"10.3390\/v13060973"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J.B., De Gregorio, E., Geall, A.J., Brazzoli, M., and Bertholet, S. (2016). Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161193"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Hekele, A., Bertholet, S., Archer, J., Gibson, D.G., Palladino, G., Brito, L.A., Otten, G.R., Brazzoli, M., Buccato, S., and Bonci, A. (2013). Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect., 2.","DOI":"10.1038\/emi.2013.54"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Lindgren, G., Ols, S., Liang, F., Thompson, E.A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., and Hassett, K.J. (2017). Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01539"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Zhuang, X., Qi, Y., Wang, M., Yu, N., Nan, F., Zhang, H., Tian, M., Li, C., Lu, H., and Jin, N. (2020). mRNA Vaccines Encoding the HA Protein of Influenza a H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice. Vaccines, 8.","DOI":"10.3390\/vaccines8010123"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Rts, S.C.T.P. (2014). Clinical Trials Partnership. Efficacy and safety of the RTS, S\/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001685"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Young, W.C., Carpp, L.N., Chaudhury, S., Regules, J.A., Bergmann-Leitner, E.S., Ockenhouse, C., Wille-Reece, U., de Camp, A.C., Hughes, E., and Mahoney, C. (2021). Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS, S\/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. Front Big Data, 4.","DOI":"10.3389\/fdata.2021.672460"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","article-title":"Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants","volume":"100","author":"Jongo","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria Vaccines: Recent Advances and New Horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41587-021-00983-8","article-title":"Malaria vaccine wows and seeds COVID-19 vaccine effort","volume":"39","author":"Ledford","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41586-020-2220-1","article-title":"Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria","volume":"582","author":"Raj","year":"2020","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chom.2021.05.012","article-title":"HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens","volume":"29","author":"Fischer","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: Optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Moyo, N., Wee, E., Korber, B., Bahl, K., Falcone, S., Himansu, S., Wong, A., Dey, A., Feinberg, M., and Hanke, T. (2020). Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. Vaccines, 8.","DOI":"10.3390\/vaccines8030360"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Awasthi, S., Hook, L.M., Pardi, N., Wang, F., Myles, A., Cancro, M.P., Cohen, G.H., Weissman, D., and Friedman, H.M. (2019). Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci. Immunol., 4.","DOI":"10.1126\/sciimmunol.aaw7083"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Egan, K.P., Hook, L.M., Naughton, A., Pardi, N., Awasthi, S., Cohen, G.H., Weissman, D., and Friedman, H.M. (2020). An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection. PLOS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008795"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1016\/j.vaccine.2020.09.079","article-title":"Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine","volume":"38","author":"LaTourette","year":"2020","journal-title":"Vaccine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Walsh, E.E., Frenck, R., Falsey, A.R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M.J., and Bailey, R. (2020). RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study. medRxiv.","DOI":"10.1101\/2020.08.17.20176651"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Ji, R.R., Qu, Y., Zhu, H., Yang, Y., Vogel, A.B., Sahin, U., Qin, C., and Hui, A. (2021). BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19. Vaccines, 9.","DOI":"10.3390\/vaccines9040324"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_143","first-page":"18","article-title":"Meeting the Demand for Lipid Excipients","volume":"34","author":"Challener","year":"2021","journal-title":"BioPharm Int."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1039\/C4CC07849G","article-title":"Fouling in microstructured devices: A review","volume":"51","author":"Schoenitz","year":"2015","journal-title":"Chem. Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"429A","DOI":"10.1021\/ac053496h","article-title":"When microfluidic devices go bad. How does fouling occur in microfluidic devices, and what can be done about it?","volume":"77","author":"Mukhopadhyay","year":"2005","journal-title":"Anal. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S.O., and Petsch, B. (2021). mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines, 6.","DOI":"10.1038\/s41541-021-00311-w"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 A phase 1 randomized clinical trial","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien Klin Wochenschr."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Kremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J.J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., and Schindler, C. (2020). Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers. medRxiv.","DOI":"10.1101\/2020.11.09.20228551"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Kremsner, P.G., Guerrero, R.A.A., Arana-Arri, E., Martinez, G.J.A., Bonten, M., Chandler, R., Corral, G., de Block, E.J.L., Ecker, L., and Gabor, J.J. (2021). Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate in Ten Countries in Europe and Latin America (HERALD): A Randomised, Observer-Blinded, Placebo-Controlled, Phase 2b\/3 Trial. Lancet Infect Dis.","DOI":"10.2139\/ssrn.3911826"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"van Doremalen, N., Fischer, R.J., Schulz, J.E., Holbrook, M.G., Smith, B.J., Lovaglio, J., Petsch, B., and Munster, V.J. (2021). Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses, 13.","DOI":"10.1101\/2021.07.07.451505"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2021","journal-title":"Nature"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Hoffmann, D., Corleis, B., Rauch, S., Roth, N., M\u00fche, J., Halwe, N.J., Ulrich, L., Fricke, C., Sch\u00f6n, J., and Kraft, A. (2021). CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. Nat. Commun., 12.","DOI":"10.1038\/s41467-021-24339-7"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Gaj, T., Sirk, S.J., Shui, S.-L., and Liu, J. (2016). Genome-Editing Technologies: Principles and Applications. Cold Spring Harb. Perspect. Biol., 8.","DOI":"10.1101\/cshperspect.a023754"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1089\/hum.2020.137","article-title":"Treating Cystic Fibrosis with mRNA and CRISPR","volume":"31","author":"Sanchez","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41551-019-0357-8","article-title":"Adenine base editing in an adult mouse model of tyrosinaemia","volume":"4","author":"Song","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref_161","first-page":"1","article-title":"Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"E781","DOI":"10.1002\/ijc.27361","article-title":"Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo","volume":"131","author":"Lee","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.nano.2012.11.006","article-title":"Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA","volume":"9","author":"Tam","year":"2013","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.10.015","article-title":"PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake","volume":"291","author":"Parhiz","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1073\/pnas.1912012117","article-title":"Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood\u2013brain barrier","volume":"117","author":"Greineder","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNP","volume":"29","author":"Tombacz","year":"2021","journal-title":"Mol Ther."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Kim, M., Jeong, M., Hur, S., Cho, Y., Park, J., Jung, H., Seo, Y., Woo, H.A., Nam, K.T., and Lee, K. (2021). Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv., 7.","DOI":"10.1126\/sciadv.abf4398"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Gan, Z., Lokugamage, M.P., Hatit, M.Z.C., Loughrey, D., Paunovska, K., Sato, M., Cristian, A., and Dahlman, J.E. (2020). Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands. Bioeng. Transl. Med., 5.","DOI":"10.1002\/btm2.10161"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:17:24Z","timestamp":1760134644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":168,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["pharmaceutics14020398"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14020398","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}